Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection
We have recently developed human-like monoclonal antibodies (mAbs) from vaccinia virus-immunized non-human primates. Two mAbs targeting the two infectious forms of the virus, were selected for in vivo evaluation, based on their in vitro neutralization potency.
A combination of both mAbs confers full protection against a lethal ectromelia virus challenge even when provided five days post infection. This combined mAbs treatment further confers post-exposure protection against the currently circulating Monkeypox virus, highlighting their therapeutic potential against other orthopoxviruses.